RxDoctor Payments Data

Paul Genilo, MD

Neurology · Wichita, KSNPI 1982609681

Payments from drug & device makers

$830in general payments, 2019–2025

Across 50 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$136
  • Lundbeck LLC$97
  • AbbVie$81
  • TG Therapeutics, Inc.$59
  • Globus Medical$55
  • Eisai Inc.$50
  • plus $353 from 14 others

What the payments were for

  • Food & beverage$830100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$830 in reported general payments places this provider in the 45th percentile of 131 neurology providers in Kansas.

See all neurology providers in Kansas

Medicare billing

Part B allowed, 2024
$354,662
Medicare patients
850
Services billed
24,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone26$738,438
CopaxoneGlatiramer Acetate27$151,659
BetaseronInterferon Beta-1b15$144,415
IngrezzaValbenazine Tosylate19$135,889
TysabriNatalizumab13$106,125
GlatopaGlatiramer Acetate28$75,667
Teriflunomide31$63,992
NuplazidPimavanserin Tartrate12$56,344
Aimovig AutoinjectorErenumab-Aooe45$41,000
BotoxOnabotulinumtoxina29$39,091
AptiomEslicarbazepine Acetate19$35,997
QuliptaAtogepant30$34,847
UbrelvyUbrogepant26$31,606
Lamotrigine OdtLamotrigine26$22,376
Emgality PenGalcanezumab-Gnlm25$18,379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys, Tysabri$32$844,56339 claims
AbbVieBotox, Qulipta, Ubrelvy$81$105,54385 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 131 neurology providers in Kansas.

Other neurology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →